Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9484674 | 0.93 | ALDH1A1 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL17480135 | 0.93 | ALDH1A1 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL17929597 | 0.93 | ALDH1A1 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL5471050 | 0.91 | STAT3 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL115398 | 0.91 | STAT3 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL5471045 | 0.91 | STAT3 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL4621606 | 0.91 | STAT3 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL2548351 | 0.91 | STAT3 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL2548348 | 0.91 | STAT3 (0.43) | STAT3ALDH1A1GAACA1CA2 | |
| SCHEMBL25382784 | 0.90 | CA1 (0.42) | STAT3ALDH1A1GAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605471-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240058480-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-20 | — | — | US | disclosed |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-10738063-B2 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | PFIZER INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10576171-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3567033-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | The General Hospital Corporation (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20190300546-A1 | 6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE COMPOUNDS | PFIZER (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190231910-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2019-08-01 | — | — | US | disclosed |
| WO-2015061397-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSTPITAL CORPORATION (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-8617517-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120058049-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2012-03-08 | — | — | US | disclosed |
| US-20120058049-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2012-03-08 | — | — | US | disclosed |
| WO-2010088455-A2 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2010-08-05 | — | — | WO | disclosed |
| US-5886190-A | REACTING GLYCEROL-1,3-DITOSYLATE-2-O-ACETYLATE WITH 2-NITROIMIDAZOLE TO FORM CHEMICAL INTERMEDIATE 1-(2'-NITRO-1'-IMIDAZOLYL)-2-O-ACETYL-3-O-TOSYLPROPANOL IN PRESENCE OF DIMETHYLFORMAMIDE AND CESIUM CARBONATE | WALLACE SIDNEY (US) | 1999-03-23 | — | — | US | disclosed |
| US-5728843-A | POSITRON EMISSION TOMOGRAPHY(PET) TO DIFFERENTIATE METABOLICALLY ACTIVE HYPOXIC TUMOR CELLS | WALLACE TECHNOLOGIES (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1995009844-A1 | RAPID SYNTHESIS AND USE OF 18F-FLUOROMISONIDAZOLE AND ANALOGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576171-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | STAT3 3477/4885ALDH1A1 3226/4885GAA 1692/4885 |
| US-12605471-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, APP, PSEN2 | STAT3 1897/4885ALDH1A1 3176/4885GAA 4063/4885 |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | STAT3 3655/4885ALDH1A1 3040/4885GAA 1308/4885 |
| US-20240058480-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, PSEN2, CROCC | STAT3 3642/4885ALDH1A1 3053/4885GAA 1525/4885 |
| US-20190300546-A1 | 6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE COMPOUNDS | PDE4B, PDE5A, PDE3B | STAT3 3382/4885ALDH1A1 150/4885GAA 1441/4885 |
| US-10738063-B2 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | PDE4B, PDE5A, PDE3B | STAT3 3382/4885ALDH1A1 150/4885GAA 1441/4885 |
| US-20190231910-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, PSEN2, CROCC | STAT3 3477/4885ALDH1A1 3226/4885GAA 1692/4885 |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | CD68, PRNP, HTT | STAT3 486/4885ALDH1A1 3735/4885GAA 613/4885 |
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, PSEN2, CROCC | STAT3 3642/4885ALDH1A1 3053/4885GAA 1525/4885 |
| US-20120058049-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | CLN6, CA6, GALNT6 | STAT3 3818/4885ALDH1A1 3021/4885GAA 2158/4885 |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | STAT3 3642/4885ALDH1A1 3053/4885GAA 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.